Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 5Colorectal Neoplasms 2Appendiceal Neoplasms 2Anus Neoplasms 2Uterine Neoplasms 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pleural Neoplasms 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Mediastinal Neoplasms 1HIV Infections 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anal Canal Carcinoma 1

Interventions

Capecitabine 41Oxaliplatin 39Fluorouracil 29Leucovorin 23Radiotherapy 21Cetuximab 14Bevacizumab 14Irinotecan 13Nivolumab 12Magnetic Resonance Spectroscopy 11Specimen Handling 9Surgical Procedures, Operative 8Folfox protocol 8Drug Therapy 8pembrolizumab 7Radiotherapy, Intensity-Modulated 7Chemoradiotherapy 7Biopsy 7trifluridine tipiracil drug combination 6Radiation 6tislelizumab 5sintilimab 5regorafenib 5dehydroftorafur 5X-Rays 5Surveys and Questionnaires 5Sigmoidoscopy 5Endoscopy 5Consolidation Chemotherapy 5spartalizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Mitozytrex × 1 year × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡